- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
13 result(s) found for: HIV vaccine development.
Displaying page 1 of 1.
EudraCT Number: 2017-003081-27 | Sponsor Protocol Number: EHVAT01/ANRSVRI05 | Start Date*: 2018-02-19 | |||||||||||
Sponsor Name:Inserm-ANRS | |||||||||||||
Full Title: EHVA T01(European HIV Vaccine Alliance Therapeutic Trial 01)/ANRS VRI05: A Phase I/II randomised therapeutic HIV vaccine trial in individuals who started antiretrovirals during primary or chronic i... | |||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) FR (Prematurely Ended) ES (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002193-23 | Sponsor Protocol Number: HLS04/2011 | Start Date*: 2011-09-27 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE) | |||||||||||||
Full Title: Long term Immunogenicity of Quadrivalent Human Papillomavirus vaccine (Gardasil) in HIV-infected adolescents and young adults vs. healthy adolescents and young adults: non-randomized controlled cli... | |||||||||||||
Medical condition: HIV+ teenagers and young adults versus HIV-negative subjects: high-risk population for HPV-related disease. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002818-40 | Sponsor Protocol Number: EHVA_T02/ANRS_VRI07 | Start Date*: 2019-10-25 | |||||||||||
Sponsor Name:Inserm-ANRS | |||||||||||||
Full Title: A Phase II randomised, placebo-controlled trial of vedolizumab with or without therapeutic HIV MVA vaccine in individuals who started antiretrovirals during primary or chronic infection | |||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003953-43 | Sponsor Protocol Number: VAC31518COV3005 | Start Date*: 2021-11-29 | ||||||||||||||||
Sponsor Name:Janssen Vaccines & Prevention B.V. | ||||||||||||||||||
Full Title: A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older | ||||||||||||||||||
Medical condition: Healthy Volunteers (Prevention of COVID-19 and influenza) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Completed) BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-003666-13 | Sponsor Protocol Number: VAC89220HPX3002 | Start Date*: 2019-10-15 | |||||||||||
Sponsor Name:Janssen Vaccines & Prevention B.V. | |||||||||||||
Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1... | |||||||||||||
Medical condition: Prevention of HIV-1 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Restarted) PL (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005466-34 | Sponsor Protocol Number: HPVAIN1 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Academic Medical Center | |||||||||||||
Full Title: Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men | |||||||||||||
Medical condition: HPV16-induced intra-anal high-grade AIN (grade 2-3) in HIV+ men, that was resistant to, or recurred after conventional cauterization or other forms of local treatment. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011529-15 | Sponsor Protocol Number: GHB-CS04, VIE-CS-002 | Start Date*: 2010-05-26 | |||||||||||
Sponsor Name:AVIR Green Hills Biotechnology Research Development Trade AG | |||||||||||||
Full Title: A Phase II Prospective, Randomised, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of the Influenza Vaccine GHB11L1 Administered Intranasally Against a Controlled Influenza Virus Cha... | |||||||||||||
Medical condition: Prophylaxis of Influenza A (H1N1) infection. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003643-29 | Sponsor Protocol Number: VAC31518COV3009 | Start Date*: 2020-11-10 | |||||||||||
Sponsor Name:Janssen Vaccines & Prevention B.V. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older E... | |||||||||||||
Medical condition: Healthy Volunteers, with or without comorbidities (Prevention of SARS-CoV-2-mediated COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) ES (Temporarily Halted) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006710-36 | Sponsor Protocol Number: V116-007 | Start Date*: 2022-08-29 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator- Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults Living With HIV | |||||||||||||
Medical condition: Pneumococcal disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004301-32 | Sponsor Protocol Number: TMC278HTX2002 | Start Date*: 2019-09-16 | |||||||||||
Sponsor Name:Janssen Sciences Ireland UC | |||||||||||||
Full Title: A Phase 2, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <... | |||||||||||||
Medical condition: HIV-1 Infection | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) PT (Completed) IT (Completed) Outside EU/EEA RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004433-14 | Sponsor Protocol Number: A3L15 | Start Date*: 2012-04-10 | ||||||||||||||||||||||||||
Sponsor Name:Sanofi Pasteur SA | ||||||||||||||||||||||||||||
Full Title: Randomized, open, controlled, multicenter, Phase III trial in infants who will receive DTaP-IPV-Hep B-PRP-T (Group 1, N=286), CombAct-Hib™ and Engerix B™ Pediatric with OPV (Group 2, N=286), or DTa... | ||||||||||||||||||||||||||||
Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, prevention against invasive infections caused by Haemophilus i... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004356-16 | Sponsor Protocol Number: D8850C00002 | Start Date*: 2020-11-18 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 a... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002128-10 | Sponsor Protocol Number: BP39144 | Start Date*: 2016-09-14 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: An adaptive Phase I/II study to assess safety, efficacy, pharmacokinetics and pharmacodynamics of RO7112689 in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH) | |||||||||||||
Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) DE (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
